1.85

4.52% 0.08

After Hours: 1.87 0.02 +1.08%

Sellas Life Sciences Group Inc (SLS)

Overview News Price History Option Chain Financials Why SLS Down? Discussions Forecast Stock Split

Sellas Life Sciences Group Inc stock is traded at $1.85, with a volume of 3.06M. It is up +4.52% in the last 24 hours and up +20.13% over the past month. SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Previous Close:

$1.77

Open:

$1.77

24h Volume:

3.06M

Relative Volume:

1.03

Market Cap:

$184.59M

Revenue:

Net Income/Loss:

$-37.34M

P/E Ratio:

-1.3603

EPS:

-1.36

Net Cash Flow:

$-36.91M

1W Performance:

-6.57%

1M Performance:

+20.13%

6M Performance:

+60.87%

1Y Performance:

+66.67%

1-Day Range:

$1.765

$1.94

1-Week Range:

$1.76

$2.09

52-Week Range:

$0.772

$2.2691

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Name

Sellas Life Sciences Group Inc

Sector

Healthcare (1161)

Industry

Biotechnology (654)

Phone

(646) 200-5278

Address

7 TIMES SQUARE, NEW YORK, NY

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

SLS's Discussions on Twitter

Compare SLS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLS Sellas Life Sciences Group Inc	1.85	197.56M	0	-37.34M	-36.91M	-1.36
VRTX Vertex Pharmaceuticals Inc	458.49	121.30B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	545.53	61.60B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	320.52	41.17B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	566.14	34.35B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	291.93	27.29B	3.81B	-644.79M	-669.77M	-6.24

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-21-21	Initiated	Cantor Fitzgerald	Overweight
Nov-01-18	Initiated	Oppenheimer	Outperform
Apr-02-18	Initiated	H.C. Wainwright	Buy
Mar-19-18	Upgrade	Maxim Group	Hold → Buy

Sellas Life Sciences Group Inc Stock (SLS) Latest News

02:14 AM

SELLAS Life Sciences Group Inc. Stock Analysis and ForecastTremendous financial leverage - jammulinksnews.com

02:14 AM

Jul 21, 2025

What drives SELLAS Life Sciences Group Inc. stock priceUnprecedented market success - Autocar Professional

Jul 21, 2025

autocarpro> 2025> What drives SELLAS Life Sciences Group Inc. stock priceOver 200% growth - Autocar Professional

Jul 21, 2025

What analysts say about SELLAS Life Sciences Group Inc. stockTremendous growth potential - Autocar Professional

Jul 21, 2025

Jul 20, 2025

Is SELLAS Life Sciences Group Inc. a good long term investmentExplosive capital appreciation - PrintWeekIndia

Jul 20, 2025

What makes SELLAS Life Sciences Group Inc. stock attractive to long term investorsMomentum Swing Watchlist - beatles.ru

Jul 20, 2025

Jul 18, 2025

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Expected to Rise, Maxim Group Analyst Says - Defense World

Jul 18, 2025

Jul 16, 2025

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities - Finansavisen

Jul 16, 2025

Sellas Life Sciences shares fall 1.58% premarket after meeting primary endpoints in Phase 2 trial. - AInvest

Jul 16, 2025

SELLAS Meets All Primary Endpoints in Phase 2 Trial of - GlobeNewswire

Jul 16, 2025

Jul 15, 2025

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success - insights.citeline.com

Jul 15, 2025

What makes SELLAS Life Sciences Group Inc. stock price move sharplyReal Time Breakout Tracking - Newser

Jul 15, 2025

How SELLAS Life Sciences Group Inc. stock performs during market volatilityHigh Yield Opportunities - Newser

Jul 15, 2025

Sellas Flat on Trial Success - Baystreet.ca

Jul 15, 2025

Sellas Life Sciences Meets Primary Endpoints in Mid-Stage SLS009 Trial - MarketScreener

Jul 15, 2025

SELLAS gains on mid-stage trial win for leukemia drug (SLS) - Seeking Alpha

Jul 15, 2025

SELLAS' Phase 2 Study Of SLS009 In Acute Myeloid Leukemia Meets All Primary Goals - Nasdaq

Jul 15, 2025

Why SELLAS Life Sciences Group Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser

Jul 15, 2025

SELLAS Life Sciences Group Reports Positive Phase 2 Trial Results for SLS009 in Relapsed/Refractory Acute Myeloid Leukemia - Nasdaq

Jul 15, 2025

SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study - The Manila Times

Jul 15, 2025

Jul 10, 2025

SELLAS Life Sciences Soars 14.21% on Key Appointment - AInvest

Jul 10, 2025

Jul 09, 2025